IGF-1 LR3 Results: Week-by-Week Timeline (2026)

10 days on, 4 weeks off — but the IGF-1 elevation runs longer than the dosing window. What community reports and animal data show at each stage.

The most common question users ask after starting an IGF-1 LR3 cycle: "When am I supposed to feel something?"

Research-context information only. IGF-1 LR3 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

The honest answer: the published research base for LR3 IGF-1 is almost entirely animal data, and the human clinical record for the analog used at community doses is essentially blank. What follows pulls together what the animal literature documents at specific time points, what community protocols report across the standard 10-day on / 4-week off pattern, and where the two sources agree or diverge.

This is a reporting article — it covers what has been documented, not what should be done. Expect a more conservative timeline than community marketing tends to suggest.

Table of Contents

• What "Results" Actually Means With IGF-1 LR3
• Week-by-Week Timeline (Standard 10-Day Cycle)
• Multi-Cycle Patterns (3-6 Months)
• Biomarker Watch: What Studies and Community Monitoring Track
• What Determines Where Results Land in the Range
• What Does NOT Typically Happen
• Related Reading
• References

What "Results" Actually Means With IGF-1 LR3

Three context points before any week-by-week breakdown:

1. The dosing window is short. The most commonly referenced community protocol is 50 mcg per day for 10 consecutive days, followed by 4 weeks off ( see dosing guide ). That is a 10-day exposure window, not a continuous cycle. Compared to peptides that are run for 8-12 weeks, the active window is a fraction of that.

2. The half-life outlasts the injection. LR3 IGF-1 binds poorly to IGF binding proteins (IGFBPs), giving it a circulating half-life of roughly 20-30 hours versus minutes for native IGF-1 ( Tomas et al., 1993 ). Each daily injection layers on top of the previous, so plasma levels build through the 10-day window and tail off after the last dose.

3. Most "results" are signaling, not visible. Animal studies show LR3 IGF-1 increases body weight gain, nitrogen retention, and food conversion efficiency ( Tomas et al., 1993 ) and suppresses muscle protein degradation pathways within an hour ( Sacheck et al., 2004 ). These are the changes that drive eventual physique shifts. The visible part — pump, fullness, scale weight — lags the molecular activity by days to weeks.

With those caveats in place, here is what the data and community sources describe at each phase.

Week-by-Week Timeline (Standard 10-Day Cycle)

Days 1-3: Loading Phase — Mostly Subjective

The first 2-3 days of a 10-day cycle are when plasma LR3 IGF-1 is climbing toward steady-state. Animal data shows the molecular changes happen fast — atrogin-1 mRNA suppression within 1 hour of IGF-1 exposure ( Sacheck et al., 2004 ) — but the visible/subjective changes lag.

What animal models and community sources describe:

• Anti-catabolic signaling activates within hours. Sacheck et al. demonstrated that IGF-1 reduced atrogin-1 expression within 1 hour by blocking mRNA synthesis, with MuRF1 suppression following more gradually. Both are E3 ubiquitin ligases that drive muscle protein breakdown ( Sacheck et al., 2004 ).
• Mild hypoglycemic awareness. Community reports during the first 2-3 days frequently describe lightheadedness or shakiness if injections are timed away from food. This is the most reproducible early signal users describe and is consistent with IGF-1's insulin-like activity.
• Possible appetite shift. Some users self-report increased hunger; others describe no change. Animal data on food conversion efficiency suggests calories are partitioned more aggressively toward lean tissue ( Tomas et al., 1993 ), but appetite responses are variable.

What is unlikely at this stage: Visible muscle changes, scale weight gain, or measurable strength shifts. Users who expect dramatic early visual changes typically describe disappointment in this window.

Community starting-dose pattern: A subset of community protocols use 20 mcg for the first 2-3 days to assess hypoglycemia response before stepping up to 50 mcg. This is reported as a tolerance check, not a therapeutic loading strategy.

Days 4-7: Peak Window

By day 4-5, plasma LR3 IGF-1 has accumulated across multiple half-lives. Animal data on continuous LR3 infusion shows organ-level effects emerge in this window — Bastian et al. measured significantly increased fractional weights of adrenals, gut, kidneys, and spleen after just 7 days of LR3 IGF-1 infusion in guinea pigs ( Bastian et al., 1995 ).

What community sources most consistently report:

• Muscle fullness and pump. The most reproducible subjective signal. Trained muscles feel rounder and more vascular during and immediately after training. This pattern is reported across forums and is consistent with IGF-1's known effects on intracellular hydration and protein synthesis through PI3K/Akt/mTOR ( Yoshida & Delafontaine, 2020 ).
• Improved training output. Some users describe modestly higher work capacity — extra reps at the same load, faster between-set recovery. This is anecdotal and not supported by controlled human trials specific to LR3.
• Weight changes are usually water/glycogen. Scale weight typically rises 1-3 lbs in this window. Animal data confirms increased nitrogen retention with LR3 IGF-1 ( Tomas et al., 1993 ), but most of the visible scale movement during a 10-day cycle reflects increased intracellular water and glycogen rather than new contractile protein.

Hypoglycemia awareness peaks here. Community reports describe the days 4-7 window as the period of greatest blood-sugar awareness, with several users describing the need for fast carbs on hand. This is consistent with IGF-1's insulin-like activity at the IGF-1 receptor and at insulin receptors at higher concentrations.

Days 8-10: Final Doses + Trailing Effects

The last three injections layer onto an already-elevated plasma level. Animal data on LR3 infusion in pigs showed continued suppression of plasma growth hormone (~23% decrease) and IGFBP-3 across the 4-day infusion window ( Tomas et al., 1997 ) — by days 8-10 of a 10-day human community protocol, this kind of HPG-axis suppression would be expected to be active.

What community sources describe:

• Sustained pump and fullness. Most consistent peak window of the cycle.
• Scale weight stabilizing. Most weight gain (water + glycogen) has occurred by this point. Continued weight gain is uncommon within a single 10-day window.
• Mild fatigue or lethargy in some users. Reported variably. Mechanism is unclear; speculation includes endogenous IGF-1 axis suppression or downstream insulin/glucose dynamics.

End of injection schedule: The last injection on day 10 still produces 20-30 hours of meaningful plasma activity. Effects do not abruptly stop on day 11.

Days 11-14: Tail-Off and Early Washout

The first 3-4 days after the last injection are not "off-cycle" in any biological sense. LR3 IGF-1 from the day-10 dose is still active for the first day, and the downstream protein-synthesis signaling continues for some period after.

What animal and community sources suggest:

• Continued anabolic carryover. The intracellular signaling cascades activated during dosing — PI3K/Akt/mTOR for synthesis, FoxO suppression for anti-catabolism — do not terminate immediately when plasma LR3 clears ( Yoshida & Delafontaine, 2020 ).
• Some community users describe their best gym sessions in this window. Glycogen stores are full, fullness is still present, and recovery feels enhanced. This is anecdotal.
• Endogenous IGF-1 is suppressed. In the pig data, plasma IGF-1, IGFBP-3, and growth hormone were all reduced by LR3 infusion ( Tomas et al., 1997 ). Recovery of the natural axis takes time and is one of the rationales for the 4-week off period.

Weeks 3-4: Post-Cycle Washout

By 2-4 weeks after the last injection, plasma LR3 has long cleared, and the body is restoring its own IGF-1 production. This is when community sources describe the most honest assessment of "what the cycle did."

What sources describe:

• Most water/glycogen weight has dropped. Scale weight typically settles 1-3 lbs above pre-cycle baseline if any retention occurred.
• Strength sometimes plateaus or regresses slightly. Without continued anabolic signaling, training stimuli must drive any maintained gains. Users without consistent training programs frequently describe losing what they thought they gained.
• Sleep, appetite, and energy normalize. Hypoglycemia awareness fades. Endogenous GH and IGF-1 axis recovery is in progress but not necessarily complete at 4 weeks.

The 4-week off-cycle is a recovery period, not a maintenance period. Animal data showing endogenous IGF-1 suppression during LR3 use ( Bastian et al., 1995 ; Tomas et al., 1997 ) is the basis for keeping the off-period at least 3-4x longer than the on-period.

Ready to buy? Compare verified vendors on our best IGF-1 LR3 sources page, or browse all coupon codes for up to 50% off.

Multi-Cycle Patterns (3-6 Months)

A single 10-day cycle is a brief exposure. Most community sources reporting visible physique changes describe multiple cycles spaced by the standard 4-week washout — typically 3-4 cycles over 4-6 months.

What this looks like across 4 cycles (roughly 5 months):

This is community-reported pattern data, not clinical trial data. No published study has tracked LR3 IGF-1 across multiple human cycles for body composition endpoints.

Important variability: Users who train hard, eat in a measured surplus or recomp, sleep well, and run cycles consistently report meaningfully different outcomes than users running cycles without nutrition or training discipline. The peptide amplifies inputs — it does not replace them.

Biomarker Watch: What Studies and Community Monitoring Track

Animal data and community monitoring protocols converge on a small set of biomarkers worth tracking before, during, and after IGF-1 LR3 cycles.

Total IGF-1

The headline marker. In the pig LR3 IGF-1 study, plasma endogenous IGF-1 was suppressed during infusion ( Tomas et al., 1997 ), and the guinea pig study showed reduced plasma IGF-I and IGF-II during LR3 administration ( Bastian et al., 1995 ). Lab assays typically measure both endogenous IGF-1 and exogenous LR3 IGF-1, so on-cycle values can be misleading. Most community monitoring protocols draw IGF-1 either pre-cycle or 2-4 weeks post-cycle.

Fasting Glucose and Insulin

The most clinically relevant marker for IGF-1 LR3's safety profile. IGF-1 has insulin-like activity, and hypoglycemia is the most reproducible acute side effect community sources describe. Fasting glucose drift downward during cycles is consistent with this mechanism.

HbA1c

Reflects 2-3 month average glucose. Less responsive to a single 10-day cycle than to a multi-cycle pattern. Community monitoring protocols often run HbA1c at baseline and after 3-4 cycles to track cumulative glycemic impact.

IGFBP-3

Animal data consistently shows LR3 IGF-1 suppresses IGFBP-3 ( Tomas et al., 1997 ; Bastian et al., 1995 ). IGFBP-3 is the major carrier protein for circulating IGF-1, and suppression has implications for endogenous IGF-1 bioavailability post-cycle. Less commonly tracked in community protocols but informative.

Complete Blood Count

Standard safety panel. Hematocrit shifts are not a documented LR3 IGF-1 effect, but a baseline panel is the cheapest way to catch unexpected changes.

What Studies Have NOT Demonstrated in Humans

Despite community claims, no controlled human trial has demonstrated:

• A specific body fat percentage reduction attributable to LR3 IGF-1 cycling
• A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern
• Cardiovascular safety endpoints across repeated cycles
• Long-term cancer-incidence data for cycled LR3 IGF-1 use

Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns ( Yoshida & Delafontaine, 2020 ), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use. The evidence base does not extend to a confident statement that cycled use is safe long-term — it simply is not studied.

What Determines Where Results Land in the Range

Community reports of LR3 IGF-1 results vary widely. The factors that most consistently predict the difference between "noticed nothing" and "best cycle of my life":

Training Stimulus

LR3 IGF-1 amplifies training-driven protein synthesis. Without progressive overload and adequate volume, the anabolic signaling has nothing to act on. Animal models of localized IGF-1 overexpression show muscle hypertrophy is satellite cell-dependent (PMID 10632630), and satellite cell activation in humans requires mechanical loading. Sedentary use of LR3 IGF-1 is the most common reason community users describe seeing nothing.

Caloric Intake

LR3 IGF-1 improves nutrient partitioning toward lean tissue ( Tomas et al., 1993 ), but it cannot create lean mass from a deficit large enough to also strip muscle. Animal data showed LR3 ameliorated body weight loss in food-restricted rats but did not preserve skeletal muscle in adult animals ( Tomas et al., 2001 ). Most community gain reports come from a small surplus or maintenance with structured training.

Dose

The standard community protocol is 50 mcg/day. Community variants run 20-100 mcg/day; some advanced users push higher with proportionally higher hypoglycemia awareness. Underdosing — running 10-20 mcg/day chronically — is one of the more common reasons community users describe seeing nothing.

Stack Versus Solo

Some community sources stack LR3 IGF-1 with a GH secretagogue ( CJC-1295/Ipamorelin , MK-677 ) or recovery peptides like BPC-157 . Stacking is reported to amplify the felt response, but no controlled comparison of solo versus stacked LR3 IGF-1 protocols exists in the literature.

Product Quality

Research-grade LR3 IGF-1 used in published animal studies has verified purity. Vendor-sourced product without third-party COA verification can contain degraded peptide, incorrect sequences, or contaminants. Underwhelming results are sometimes a product-quality issue rather than a protocol issue. Compare verified vendors on the /best/ IGF-1 LR3 page .

Sleep, Stress, Recovery

Endogenous GH and IGF-1 production depends on sleep architecture. Chronic sleep deprivation suppresses the same axis LR3 IGF-1 is supplementing, and cortisol elevation from chronic stress drives the protein-degradation pathways LR3 IGF-1 is suppressing. Users running cycles on top of a broken recovery foundation routinely report disappointment.

What Does NOT Typically Happen

Managing expectations honestly:

• Dramatic visible changes inside a single 10-day cycle. Despite community marketing, a single cycle does not produce the kind of physique shift visible in a "before and after" photo. Most reproducible visible changes are described over 3-4 cycles, not one.
• Spot fat loss. LR3 IGF-1 is not a lipolytic compound. Animal data shows favorable nutrient partitioning, but direct fat-mobilizing effects are minimal compared to growth hormone itself ( Yoshida & Delafontaine, 2020 ).
• Site-specific muscle growth from local injection. Despite community claims, no human study has demonstrated that intramuscular LR3 IGF-1 produces preferential growth in the injected muscle. The systemic distribution of the molecule is rapid.
• Permanent IGF-1 elevation. The peptide clears. Endogenous IGF-1 is suppressed during use ( Tomas et al., 1997 ) and recovers across the off-period.
• No hypoglycemia risk at low doses. Community reports describe blood-sugar awareness even at 20-30 mcg in some users. There is no documented "hypoglycemia-free" dose threshold.
• Continuous strength gains with consistent cycling. Diminishing returns are commonly described across multiple cycles, particularly without simultaneous training periodization.

Where to head next

You've seen the timeline — here's how to actually run a IGF-1 LR3 protocol and where to source it.

IGF-1 LR3 dosing protocol

Starting dose, titration ladder, injection frequency, and the common community-reported handling notes for IGF-1 LR3.

Top-ranked IGF-1 LR3 vendors

Ranked by price, COA, and reputation. The canonical buyer surface for IGF-1 LR3 — ready for the click when you are.

Buying IGF-1 LR3: vendor comparison

Price-per-mg, COA verification, shipping reliability — the deeper vendor survey if you want context before clicking through.

Frequently Asked Questions

Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped

70% isopropyl alcohol prep pads, individually wrapped — for cleaning the vial stopper and injection site before IGF-1 LR3 dosing.

Renpho 8-Electrode Smart Body Composition Scale

Body-composition scale — useful when IGF-1 LR3 protocols target lean-mass + recomposition.

Double Wood Magnesium Glycinate 400mg (180ct)

Magnesium glycinate — community sources cite this for the sleep-architecture shifts that elevated IGF-1 sometimes drives on GH-secretagogue protocols.

Pure Encapsulations Melatonin 0.5mg

Low-dose 0.5mg melatonin — pairs with GH-secretagogue protocols where sleep-onset slows; 0.5mg is the dose research uses, not the 5-10mg retail bottle.

Related Reading

• IGF-1 LR3 Dosing Guide — 50 mcg/day for 10 days, route, reconstitution math
• IGF-1 LR3 Benefits — five effects ranked by evidence quality
• IGF-1 LR3 Buying Guide — vendor comparison and what to look for in a COA
• IGF-1 LR3 peptide page — full profile, vendor pricing, mechanism deep-dive
• Best Peptides for Muscle Growth — how IGF-1 LR3 ranks against alternatives
• MK-677 Results Timeline — oral GH secretagogue that raises endogenous IGF-1
• CJC-1295 + Ipamorelin Dosing Guide — common stacking partner via the GH/IGF-1 axis
• BPC-157 Dosing Guide — recovery peptide commonly stacked with anabolic protocols

References

• Tomas FM, Knowles SE, Owens PC, et al. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-21. PMID: 8371075
• Bastian SE, Walton PE, Ballard FJ, Belford DA. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):245-52. PMID: 7561636
• Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1997;154(2):277-86. PMID: 9488001
• Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004;287(4):E591-601. PMID: 15100091
• Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. PMID: 32858949
• Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ. Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction. Growth Horm IGF Res. 2001;11(4):213-21. PMID: 11472075
• Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol. 1998;84(5):1716-22. PMID: 10632630

For educational and research purposes only. This is not medical advice. IGF-1 LR3 is a research compound with no FDA approval. The published research base for LR3 IGF-1 specifically is almost entirely animal data. Human clinical timeline data does not exist.

Tabelas de referência

Perguntas frequentes

How quickly does IGF-1 LR3 start working?

Animal studies show IGF-1 LR3 suppresses muscle protein degradation pathways (atrogin-1, MuRF1) within 1 hour of administration. Subjective changes — pump, fullness, mild appetite shift — are most often reported in the first 3-5 days of a 10-day cycle.

When do most users see physical changes from IGF-1 LR3?

Community reports describe visible fullness and improved training output by days 5-7 of the 10-day window. Body composition shifts — if any — are typically reported in the days following the on-cycle, as recovery and remodeling continue after dosing stops.

What happens after the 10-day on-cycle ends?

The peptide clears within 1-2 days, but published animal data show LR3 IGF-1 suppresses endogenous IGF-1 and IGFBP-3 during infusion. Community protocols use a 4-week washout to allow the natural axis to recover before the next cycle.

Is IGF-1 LR3 fast-acting or slow-building?

It is a fast-acting compound on the molecular level — protein synthesis and anti-catabolic signaling shift within hours — but cumulative physical changes are modest from a single 10-day cycle. Most users running multiple spaced cycles describe more pronounced changes over 3-6 months.

Why didn't I see results from one IGF-1 LR3 cycle?

A single 10-day cycle is a small dosing window. Underdosing, poor product quality, lack of training stimulus, and inadequate calories are the most common reasons community users report no visible change. Multiple spaced cycles are the more common pattern.

Do IGF-1 LR3 results last after stopping?

Animal data shows endogenous IGF-1 returns toward baseline after LR3 infusion ends. Tissue gains supported by training are retained, but the elevated anabolic signaling is cycle-dependent. Without continued training, lean mass advantages erode like any other anabolic protocol.

What bloodwork tracks IGF-1 LR3 effects?

Total IGF-1, fasting glucose, insulin, HbA1c, and CBC are most commonly referenced in community monitoring protocols. IGFBP-3 is informative but less commonly run. Animal data shows LR3 suppresses both endogenous IGF-1 and IGFBP-3 during use.